« Back to Record
Body, J.-J., Lichinitser, M., Tjulandin, S., Garnero, P., & Bergström, B. (2007). Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Annals of oncology, 18(7), 1165-1171. doi:10.1093/annonc/mdm119
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/83359



